CJC-1295 with DAC
Also known as: CJC-1295, CJC-1295 DAC, DAC:GRF, Modified GRF (1-29) with DAC
Source CJC-1295 with DAC at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Long-acting GHRH analog with DAC modification for extended duration; not approved for human use; investigated for growth hormone deficiency and performance enhancement
Mechanism of Action
synthetic GHRH analog that stimulates pituitary release of growth hormone; DAC (drug affinity complex) extends half-life via albumin binding
Routes of Administration
Goals & Uses
- treat growth hormone deficiencyTherapeuticModerate
- increase growth hormone levelsHormone ModulationModerate
- Improve body compositionMusculoskeletalLow
Contraindications
- Active malignancyOncologyHighUse caution or avoid depending on agent and context
- pediatric patients with closed epiphysesDevelopmentalModerate
- PregnancyPopulationHighPotential fetal risk or insufficient safety data
- Diabetic retinopathyOphthalmologyHigh
Adverse Effects
- Injection site reactionsLocalCommon
- Carpal tunnel syndromeMusculoskeletalUncommon
- HeadacheNeurologicUncommonPain in the head or upper neck
- acromegalic featuresEndocrineRare
- insulin resistanceMetabolicUncommon
- water retention/edemaMetabolicCommon
Drug Interactions
- InsulinModerateMay increase risk of low blood sugar
- GlucocorticoidsLow
- GHRPs/ghrelin mimeticsModerate
- somatostatin analogsHigh
Population Constraints
- Pediatric patientsAgeRelative
- patients with active cancer historyDiseaseAbsolute
- Patients with diabetes mellitusMetabolicRelative
- Elderly patientsAgeRelative
- competitive athletesOccupationalAbsolute
Regulatory Status
- European UnionUnapprovedNo EMA approval; considered unauthorized medicinal product
- United StatesUnapprovedNot approved by FDA; not available as prescription product
- United KingdomUnapprovedMHRA unapproved; supply as unlicensed medicine prohibited
Not approved by any major regulatory authority; classified as prohibited substance by WADA; unapproved research chemical
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is CJC-1295 with DAC?
Long-acting GHRH analog with DAC modification for extended duration; not approved for human use; investigated for growth hormone deficiency and performance enhancement
What is CJC-1295 with DAC used for?
CJC-1295 with DAC is educationally associated with: treat growth hormone deficiency, increase growth hormone levels, Improve body composition. Educational only — not medical advice.
How is CJC-1295 with DAC administered?
Recorded routes of administration: Subcutaneous.
What are the potential side effects of CJC-1295 with DAC?
Reported adverse effects include: Injection site reactions, Carpal tunnel syndrome, Headache, acromegalic features, insulin resistance, water retention/edema. This list is not exhaustive — consult a qualified clinician.
Who should avoid CJC-1295 with DAC?
Recorded contraindications: Active malignancy, pediatric patients with closed epiphyses, Pregnancy, Diabetic retinopathy. Consult a qualified clinician before use.